CD3 - Scientific Progress - Products and Research

: 中文

Products and Research

Develop innovative drugs to safeguard human health

Home > Products and Research > Scientific Progress > CD3

About CD3

CD3（Cluster of Differentiation 3）is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell and T helper cells. It is composed of four distinct chains (a CD3γ chain, a CD3δ chain and two CD3ε chains). These chains associate with the T-cell receptor (TCR) and the CD3ζ chain through the salt bridge to generate an activation signal in T lymphocytes. CD3ζ chain is a homodimer that is responsible for the generation of an activation signal in T lymphocytes The TCR, CD3 ζ and the other CD3 molecules together constitute the TCR complex.. Due to the sequence conserved nature of the CD3 chain, CD3 is often chosen as a surface target for T cells. CD3 bispecific antibody is capable of recruiting all available T cells and is not limited to tumor-specific T cells, unlike the key requirement for immune checkpoint therapies to produce efficacy. A bispecific antibody targeting CD3 needs to be considered to inhibit the effector function of Fc in order to minimize off-target toxicity and maximize therapeutic efficacy. In recent years, CD3 has been a promising target for the development of bispecific antibody for cancer therapy. Approximately 45% of all marketed and clinical-stage bispecific antibodies worldwide are targeted to CD3.

Reference

M802 exhibited potent antitumor efficacy in vitro and in vivo. M802 retained the function of Herceptin in antitumor signaling pathways, and also recruited CD3-positive immune cells to eliminate HER2-positive tumor cells.

The developed reporter gene assay was mechanism of action-reflective for the bioactivity of anti-CD38 × anti-CD3 antibody, and suitable for the quality control for the bsAb product.